Dado, what is your assessment of the Epilepsy Guidance for Partial Onset Seizures and can you explain to us laymen what is POS. Looks to me that it recognizes the extrapolation of adult data with pediatric results down to age 4 and above, except for safety. So, a trial for efficacy for adults would be extrapolated for children down to 4 but, you still have to conduct a pediatric safety follow-on trial. Is this a significant drug development improvement? Could it have application in other diseases which have as an endpoint to reduce seizures, tremors or involuntary limb and hand movement?
Market Data 
Markets 
AI
